A first‐in‐human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults

• Main Authors: Rupert Davies (Author), Stanford L. Peng (Author), Jason Lickliter (Author), Kristi McLendon (Author), Amanda Enstrom (Author), Allison G. Chunyk (Author), Lori Blanchfield (Author), NingXin Wang (Author), Tiffany Blair (Author), Heather M. Thomas (Author), Alina Smith (Author), Stacey R. Dillon (Author)
• Format: Book
• Published: Wiley, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Therapeutic agents targeting the tumor necrosis factor (TNF) superfamily cytokines B‐cell activating factor (BAFF, BLyS) and/or A PRoliferation Inducing Ligand (APRIL) have demonstrated clinical effectiveness in multiple autoimmune diseases, such as systemic lupus erythematosus, lupus nephr...